Patent classifications
A61K36/884
METHOD FOR TREATING A SIDE EFFECT CAUSED BY BCG PERFUSION THERAPY FOR BLADDER CANCER
The present invention relates to a method for treating a side effect caused by bacillus Calmette-Guérin (BCG) perfusion therapy for bladder cancer. The method includes: administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising gentiana scabra, scutellariae Radix, gardeniae fructus, angelicae sinensis Radix, rehmanniae radix, akebiae caulis, Bupleurum chinense, plantaginis Semen, Atractylodes lancea, rhizoma alismatis, and glycyrrhiza uralensis.
METHOD FOR TREATING A SIDE EFFECT CAUSED BY BCG PERFUSION THERAPY FOR BLADDER CANCER
The present invention relates to a method for treating a side effect caused by bacillus Calmette-Guérin (BCG) perfusion therapy for bladder cancer. The method includes: administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising gentiana scabra, scutellariae Radix, gardeniae fructus, angelicae sinensis Radix, rehmanniae radix, akebiae caulis, Bupleurum chinense, plantaginis Semen, Atractylodes lancea, rhizoma alismatis, and glycyrrhiza uralensis.
METHOD FOR TREATING GLIOBLASTOMA MULTIFORME
The present invention relates to a method for treating glioblastoma multiforme including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture including Boswella sacra, Commiphora molmol, Angelica sinensis, Ligusticum striatum, Rehmannia glutinosa, Paeonia veitchii, Prunus persica, and Carthamus tinctorius.
METHOD FOR TREATING GLIOBLASTOMA MULTIFORME
The present invention relates to a method for treating glioblastoma multiforme including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture including Boswella sacra, Commiphora molmol, Angelica sinensis, Ligusticum striatum, Rehmannia glutinosa, Paeonia veitchii, Prunus persica, and Carthamus tinctorius.
METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER
The present invention is directed to therapeutic methods and compositions for treating non-small cell lung cancer in a subject comprising administering an effective amount of an extract or powder of a herbal mixture, optionally with an anti-cancer agent to said subject. The herbal mixture comprises a component of at least one species from each of the genus Astragalus, Cimicifuga foetida rhizoma, Ophiopogon radix, Atractylodes lancea rhizoma, Panax ginseng-Red, Atractylodes rhizoma-White, Massa medicata fermentata, Citrus reticulata-Viride, Citrus reticulata, Glycyrrhiza radix, Schisandra fructus, Angelica sinensis radix, Phellodendron cortex, Alisma rhizoma, Pueraria radix, Ziziphus fructus-Red, and Zingiber officinale radix.
METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER
The present invention is directed to therapeutic methods and compositions for treating non-small cell lung cancer in a subject comprising administering an effective amount of an extract or powder of a herbal mixture, optionally with an anti-cancer agent to said subject. The herbal mixture comprises a component of at least one species from each of the genus Astragalus, Cimicifuga foetida rhizoma, Ophiopogon radix, Atractylodes lancea rhizoma, Panax ginseng-Red, Atractylodes rhizoma-White, Massa medicata fermentata, Citrus reticulata-Viride, Citrus reticulata, Glycyrrhiza radix, Schisandra fructus, Angelica sinensis radix, Phellodendron cortex, Alisma rhizoma, Pueraria radix, Ziziphus fructus-Red, and Zingiber officinale radix.
METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER
The present invention is directed to therapeutic methods and compositions for treating non-small cell lung cancer in a subject comprising administering an effective amount of an extract or powder of a herbal mixture, optionally with an anti-cancer agent to said subject. The herbal mixture comprises a component of at least one species from each of the genus Astragalus, Cimicifuga foetida rhizoma, Ophiopogon radix, Atractylodes lancea rhizoma, Panax ginseng-Red, Atractylodes rhizoma-White, Massa medicata fermentata, Citrus reticulata-Viride, Citrus reticulata, Glycyrrhiza radix, Schisandra fructus, Angelica sinensis radix, Phellodendron cortex, Alisma rhizoma, Pueraria radix, Ziziphus fructus-Red, and Zingiber officinale radix.
Antiviral Pharmaceutical Compositions and Method of Manufacturing
The present disclosure provides compositions comprising combinations of one or more lectins, sulfated polysaccharides from marine algae, and cannabinoids and a pharmaceutically acceptable excipient or mixtures of excipients and methods of preparing such compositions.
Antiviral Pharmaceutical Compositions and Method of Manufacturing
The present disclosure provides compositions comprising combinations of one or more lectins, sulfated polysaccharides from marine algae, and cannabinoids and a pharmaceutically acceptable excipient or mixtures of excipients and methods of preparing such compositions.
A MANUFACTURING METHOD OF AN HERBAL MEDICINAL TABLET FORMULATION FOR TREATING OBESITY WHICH CAN BE PRESCRIBED BASED ON SASANG CONSTITUTIONAL MEDICINE
An embodiment of the present invention provides a manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, comprises manufacturing a concentrated and quantified ephedra powder agent so that an ephedrine content of ephedra, which differs from 0.5-2.5% depending on a producing district and collecting period, is 3.0-4.0%, determining a weight according to each constitution of Sasang constitutional medicine of the concentrated and quantified ephedra powder agent of which the ephedrine content is 3.0-4.0%, and manufacturing a side-effect-preventing powder agent for each constitution to prevent and suppress side effects according to constitution of Sasang constitutional medicine with respect to the weight of the ephedra powder agent, preparing the ephedra powder agent and the side-effect-preventing powder agent while varying a weight ratio therebetween in consideration of weight, obesity, constitution of Sasang constitutional medicine, and side effects while mixing the ephedra powder agent and the side-effect-preventing powder agent; tableting a mixture of the prepared ephedra powder agent and side-effect-preventing powder agent; coating the tableted ones after tableting; and after the coating, while sorting out defective ones from coated ones and packaging, displaying a label including information prepared according to weight, obesity, constitution of Sasang constitutional medicine, and side effects.